ERBB2 and breast carcinoma: Besides triple-negative breast cancer, we evaluated the efficacy of the autologous blood-derived CM with 3 breast cancer subtypes, including ER+PR+HER2-, ER+PR-HER2-, and ER-PR+HER2+.